#1 Clinical Trials Search in Europe

Ranolazine

This article examines the use of ranolazine, a medication primarily used to treat chronic angina, in clinical trials for various heart conditions. Ranolazine is being studied for its potential benefits in treating atrial fibrillation, ischemic cardiomyopathy, premature ventricular contractions, and other cardiac issues. The trials aim to assess the drug’s efficacy, safety, and impact on patients’ quality of life across different cardiac disorders.

Table of Contents

What is Ranolazine?

Ranolazine, also known by its brand name Ranexa®, is a medication primarily used to treat chronic angina (chest pain) in patients with coronary artery disease[1]. It is a unique anti-anginal agent that works differently from other heart medications, offering an alternative for patients who may not respond well to or cannot tolerate other treatments[2].

Conditions Treated with Ranolazine

Ranolazine is approved and studied for various cardiovascular conditions, including:

  • Chronic Angina: The primary use of ranolazine is to treat ongoing chest pain in patients with coronary artery disease[1].
  • Coronary Artery Disease (CAD): Ranolazine is used in patients with CAD, a condition where the arteries supplying blood to the heart become narrowed or blocked[1].
  • Type 2 Diabetes Mellitus: While not approved for diabetes treatment, studies have explored its effects in patients with both CAD and type 2 diabetes[1].
  • Ventricular Premature Complexes (PVCs): Research has investigated ranolazine’s potential in reducing these extra, abnormal heartbeats[2].
  • Atrial Fibrillation: Studies have looked at ranolazine’s effectiveness in maintaining normal heart rhythm after electrical cardioversion in patients with atrial fibrillation (an irregular heart rhythm)[3].

Additionally, researchers have explored ranolazine’s potential benefits in other conditions:

  • Diabetic Peripheral Neuropathic Pain: A study investigated if ranolazine could help reduce pain associated with nerve damage in diabetes patients[4].
  • Myotonia Congenita, Paramyotonia Congenita, and Myotonic Dystrophy Type 1: These are rare muscle disorders where ranolazine’s effects have been studied[5].
  • Amyotrophic Lateral Sclerosis (ALS): A study is evaluating ranolazine’s potential in managing symptoms of ALS, also known as Lou Gehrig’s disease[6].

How Ranolazine Works

Ranolazine works differently from traditional heart medications. It acts on the heart cells in the following ways:

  • Sodium Current Inhibition: Ranolazine inhibits the late sodium current in heart cells. This action helps reduce the harmful effects of sodium and calcium overload that can occur during heart ischemia (reduced blood flow to the heart)[2].
  • Anti-Ischemic Effects: By balancing the electrolytes in heart cells, ranolazine helps improve the heart’s efficiency, reducing the oxygen demand of the heart muscle. This can lead to fewer angina episodes[2].
  • Anti-Arrhythmic Properties: Studies have shown that ranolazine may help reduce various types of abnormal heart rhythms, including ventricular tachycardia and atrial fibrillation[2][3].

Importantly, ranolazine achieves these effects without significantly impacting heart rate or blood pressure, making it a unique option for patients who cannot tolerate other medications that lower these parameters[2].

Dosage and Administration

Ranolazine is typically administered orally in tablet form. The dosage and frequency can vary based on the condition being treated and individual patient factors. Here are some common dosing regimens observed in clinical trials:

  • For Chronic Angina:
    • Starting dose: 500 mg twice daily
    • May be increased to: 1000 mg twice daily, as tolerated
    • Duration: Often prescribed for continuous use
  • For Research in Other Conditions:
    • Doses ranging from 500 mg to 1000 mg twice daily have been studied
    • Treatment durations varied from a few weeks to several months, depending on the study

It’s crucial to take ranolazine exactly as prescribed by your healthcare provider. Do not adjust the dose or stop taking the medication without consulting your doctor[1][2].

Clinical Studies and Effectiveness

Numerous clinical studies have evaluated ranolazine’s effectiveness in various conditions:

  • Chronic Angina: Studies have shown that ranolazine can significantly reduce the frequency of angina episodes and improve exercise tolerance in patients with chronic stable angina[1].
  • Ventricular Premature Complexes (PVCs): Research has indicated that ranolazine may reduce the burden of PVCs in patients with ischemic heart disease[2].
  • Atrial Fibrillation: A study investigated ranolazine’s potential in maintaining normal heart rhythm after electrical cardioversion in patients with atrial fibrillation[3].
  • Diabetic Peripheral Neuropathic Pain: A trial explored whether ranolazine could reduce pain in patients with this condition[4].
  • Muscle Disorders: Research has looked into ranolazine’s effects on symptoms of certain rare muscle disorders[5].
  • ALS: An ongoing study is evaluating ranolazine’s potential benefits in managing ALS symptoms[6].

These studies have generally shown promising results, particularly in managing chronic angina. However, its effectiveness in other conditions is still being researched, and more studies are needed to fully understand its potential benefits.

Potential Side Effects

Like all medications, ranolazine can cause side effects. Common side effects reported in clinical trials include:

  • Dizziness
  • Headache
  • Constipation
  • Nausea

More serious side effects, though less common, may include:

  • Changes in heart rhythm (arrhythmias)
  • Allergic reactions

It’s important to report any unusual symptoms or side effects to your healthcare provider promptly[1][2].

Special Considerations

There are several important factors to consider when using ranolazine:

  • Kidney Function: Patients with severe kidney impairment may require dose adjustments or special monitoring[7].
  • Liver Function: Ranolazine is metabolized in the liver, so liver function should be monitored.
  • Drug Interactions: Ranolazine can interact with other medications. Always inform your healthcare provider about all medications you’re taking.
  • Pregnancy and Breastfeeding: The safety of ranolazine during pregnancy and breastfeeding is not well established. Discuss with your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Remember, while ranolazine has shown promise in treating various conditions, it’s crucial to use it only under the guidance of a healthcare professional. Your doctor will weigh the potential benefits against the risks for your specific situation.

Aspect Details
Primary Use Treatment of chronic angina
Conditions Studied Atrial fibrillation, ischemic cardiomyopathy, premature ventricular contractions, myotonia congenita, ALS
Measurement Methods ECG monitoring, cardiopulmonary exercise tests, quality of life questionnaires, symptom tracking
Trial Durations Ranging from 4-5 weeks to 16 weeks
Dosages Typically 500mg to 1000mg twice daily
Safety Considerations Effects in severe renal impairment, adverse event monitoring
Key Outcomes Reduction in arrhythmias, improvement in exercise capacity, reduction in angina frequency

FAQ

  • What is ranolazine and what is it primarily used for? Ranolazine is a medication primarily used to treat chronic angina (chest pain). It works by improving blood flow to help the heart work more efficiently.
  • What other heart conditions is ranolazine being studied for in clinical trials? Ranolazine is being studied for conditions such as atrial fibrillation, ischemic cardiomyopathy, premature ventricular contractions, and other cardiac issues like myotonia congenita and amyotrophic lateral sclerosis (ALS).
  • How is ranolazine's effectiveness measured in these trials? Effectiveness is measured through various means including electrocardiogram (ECG) monitoring, cardiopulmonary exercise tests, quality of life questionnaires, and tracking of symptoms like angina frequency and use of nitroglycerin.
  • Are there any potential side effects of ranolazine being studied? Yes, the trials are assessing the safety and tolerability of ranolazine. Some studies are specifically looking at its effects in patients with severe renal impairment and monitoring for any adverse events.
  • How long do these clinical trials typically last? The duration of the trials varies, ranging from a few weeks to several months. For example, some trials last 4-5 weeks, while others extend up to 16 weeks (112 days).

Ongoing Clinical Trials on Ranolazine

  • Study of ranolazine in patients with ST-elevation heart attack and multiple blocked coronary arteries to improve small blood vessel function

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Flecainide and Ranolazine for Restoring Heart Rhythm in Patients with Recent Atrial Fibrillation

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

Glossary

  • Atrial Fibrillation (AFib): An irregular and often rapid heart rate that can increase your risk of strokes, heart failure and other heart-related complications.
  • Ischemic Cardiomyopathy: A condition where the heart muscle is weakened due to insufficient blood supply, often as a result of coronary artery disease.
  • Premature Ventricular Contractions (PVCs): Extra, abnormal heartbeats that begin in one of the heart's two lower pumping chambers (ventricles).
  • Cardiopulmonary Exercise Test (CPET): A test that measures how well your heart and lungs work while you exercise on a bicycle or treadmill.
  • Electrocardiogram (ECG): A test that records the electrical activity of your heart through small electrode patches attached to the skin of your chest, arms, and legs.
  • Myotonia Congenita: A genetic disorder that affects muscle relaxation, causing muscle stiffness and difficulty releasing grip.
  • Amyotrophic Lateral Sclerosis (ALS): A progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.
  • Anaerobic Threshold (AT): The point during exercise at which lactic acid starts to accumulate in the bloodstream faster than it can be removed.
  • Peak VO2: The maximum rate of oxygen consumption measured during incremental exercise, reflecting cardiovascular fitness and aerobic endurance.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, used to evaluate lung function.

References

  1. https://clinicaltrials.gov/study/NCT01425359
  2. https://clinicaltrials.gov/study/NCT02360397
  3. https://clinicaltrials.gov/study/NCT01534962
  4. https://clinicaltrials.gov/study/NCT02156336
  5. https://clinicaltrials.gov/study/NCT02251457
  6. https://clinicaltrials.gov/study/NCT06527222
  7. https://clinicaltrials.gov/study/NCT01675973